CCClarissa Melo Czekster

Clarissa Melo Czekster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clarissa Melo Czekster has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural basis for autoinhibition and self-activation in the Pseudomonas aeruginosa virulence factor protease IV (PIV)

    by Christopher J. Harding, Carlin Hamill, Qingtian Gong, Clarissa Melo Czekster

    Secreted proteases enable Pseudomonas aeruginosa to damage host tissues and evade host immune defences, but the molecular basis by which protease IV (PIV) is maintained as an inactive precursor remains unclear. Here we determined a 2.17 A crystal structure of catalytically inactive PIVS409A. The precursor comprises an N-terminal Cap region, a CUB domain and a C-terminal trypsin-like protease domain. The Cap region forms an extended clamp across the precursor, and residues at the Cap-CUB junction lie above the catalytic cleft. Structural comparison with a modelled peptide substrate indicates that the Cap does not engage the substrate-recognition pockets as a pseudosubstrate; instead, it sterically prevents access to the S1 pocket, oxyanion hole and catalytic triad. Wild-type PIV undergoes progressive processing to a 27.6-kDa mature species, whereas the S409A variant remains resistant to activation by exogenous mature enzyme, supporting an intramolecular initiating step. Mature PIV is weakly inhibited by an ornithine-containing peptide mimicking the Cap domain, is not inhibited by phenylmethylsulfonyl fluoride and is slowly irreversibly inhibited by TLCK, demonstrating unique characteristics in comparison to other proteases from the same family. Finally, mature PIV increases the activity of aminopeptidase PaAP, likely through maturation of this enzyme, as part of a protease activation cascade. These findings define the architecture of the PIV precursor and provide a structural framework for understanding its activation and selective autoinhibition.

  • Open Access

    Bacterial Aminopeptidase-Activated Peptide Prodrug Enables Species-Selective Targeting of Pseudomonas aeruginosa

    by Qingtian Gong, Silvia Synowsky, Aisling Lynch, John R. F. B. Connolly, Neeladri Sekhar Roy, Sally L. Shirran, Megan Bergkessel, Marc Devocelle, Clarissa M. Czekster

    Pseudomonas aeruginosa is an adaptable organism, frequently found in chronic infections, and for which antimicrobial resistance is a growing concern. Therefore, there is an urgent need for alternative therapeutic strategies. Cationic antimicrobial peptides (AMPs) offer potent bactericidal activity but suffer from limited selectivity and potential host toxicity. To enhance species-specific targeting, we designed two prodrug variants of the AMP D-Bac8CLeu2,5─EEEE-D-Bac8CLeu2,5 and ELEG-D-Bac8CLeu2,5─engineered for activation by the P. aeruginosa extracellular aminopeptidase PaAP. While both prodrug motifs effectively neutralized the positive charge of D-Bac8CLeu2,5 and prevented DNA–peptide complex formation, EEEE-D-Bac8CLeu2,5 showed negligible antimicrobial activity due to slow and incomplete activation. In contrast, ELEG-D-Bac8CLeu2,5 underwent rapid PaAP-mediated activation, restoring bactericidal activity in planktonic cultures and biofilms. PaAP contributed significantly to complete prodrug activation, particularly within biofilms, where the accumulation of partially activated intermediates correlated with biphasic killing kinetics. The prodrug showed reduced activity against other ESKAPEE pathogens, demonstrating selective activation by P. aeruginosa. Experiments selecting resistant bacteria revealed distinct mutations in lipopolysaccharide biosynthesis pathways for D-Bac8CLeu2,5 and the prodrug, with limited cross-resistance. These findings establish aminopeptidase-activated AMP prodrugs as a promising approach for species-selective antimicrobial therapy and highlight the feasibility of exploiting bacterial enzymes for controlled antimicrobial peptide activation.

  • Open Access

    Bacterial Aminopeptidase–Activated Peptide Prodrug Enables Species-Selective Targeting of Pseudomonas aeruginosa

    by Qingtian Gong, Silvia Synowsky, Aisling Lynch, John R. F. B. Connolly, Neeladri Sekhar Roy, Sally L. Shirran, Megan Bergkessel, Marc Devocelle, Clarissa M. Czekster

    Pseudomonas aeruginosa is an adaptable organism, frequently found in chronic infections, and for which antimicrobial resistance is a growing concern. Therefore, there is an urgent need for alternative therapeutic strategies. Cationic antimicrobial peptides (AMPs) offer potent bactericidal activity but suffer from limited selectivity and potential host toxicity. To enhance species-specific targeting, we designed two prodrug variants of the AMP D-Bac8C Leu2,5 – EEEE□-Bac8C Leu2,5 and ELE□ D-Bac8C Leu2,5 —engineered for activation by the P. aeruginosa extracellular aminopeptidase PaAP. While both prodrug motifs effectively neutralized the positive charge of D-Bac8C Leu2,5 and prevented DNA–peptide complex formation, EEEE□-Bac8C Leu2,5 showed negligible antimicrobial activity due to slow and incomplete activation. In contrast, ELEG□-Bac8C Leu2,5 underwent rapid PaAP□mediated activation, restoring bactericidal activity in planktonic cultures and biofilms. PaAP contributed significantly to complete prodrug activation, particularly within biofilms, where the accumulation of partially activated intermediates correlated with biphasic killing kinetics. The prodrug showed reduced activity against other ESKAPEE pathogens, demonstrating selective activation by P. aeruginosa . Experiments selecting resistant bacteria revealed distinct mutations in lipopolysaccharide biosynthesis pathways for D-Bac8C Leu2,5 and the prodrug, with limited cross□resistance. These findings establish aminopeptidase□activated AMP prodrugs as a promising approach for species□selective antimicrobial therapy and highlight the feasibility of exploiting bacterial enzymes for controlled antimicrobial peptide activation.

  • Open Access

    Dimerization and Threonine-Dependent Stabilization Govern Human YRDC Catalysis

    by Ngoc Anh Thu Trinh, Greice Zickuhr, Alison L Dickson, Silvia Sinowski, Carlin Hamill, Ramasubramanian Sundaramoorthy, Tomas Lebl, Sally L Shirran, David J Harrison, Clarissa M Czekster

    Addition of N6-threonylcarbamoyladenosine occurs at position 37 (T6A37) of five mitochondrial tRNA species, influencing translation fidelity and efficiency. Mutations in YRDC, the enzyme catalyzing the first step in T6A37 synthesis, cause severe neurological and renal diseases in humans, including in Galloway-Mowatt disease (GAMOS). YRDC generates threonylcarbamoyl-AMP (TC-AMP) using ATP, threonine and bicarbonate as substrates, yet their binding order, residues involved in amino-acid selectivity, and precisely how mutations contribute to disease remain unclear. Here, we combine protein biophysics, mass spectrometry, NMR, mutagenesis and kinetics to define how the human enzyme operates. Differential scanning fluorimetry and circular dichroism identify L-threonine as the gatekeeper ligand. It binds with low-millimolar affinity, stabilizing YRDC and enhancing ATP binding tenfold, enabling bicarbonate association. Several amino acids can form aminoacylcarbamoyl-AMP adducts in vitro, but threonine yields superior protein stabilization and product formation. Native mass spectrometry and single-molecule mass photometry corroborate the dimeric state of YRDC. GAMOS-linked mutations destabilize folding, disrupting dimerization and uncoupling substrate binding from catalysis, explaining functional losses. Supported by kinetic data and NMR, we put forward a chemical mechanism for the reaction and identify dimerization and conformational stability as control points for activity. This work provides a foundation for designing selective YRDC inhibitors or enhancers.

  • Open Access

    Improved Nucleoside (2′-Deoxy)Ribosyltransferases Maximize Enzyme Promiscuity while Maintaining Catalytic Efficiency

    by Peijun Tang, Greice M. Zickuhr, Alison L. Dickson, Christopher J. Harding, Suneeta Devi, Tomas Lebl, David J. Harrison, Rafael G. da Silva, Clarissa M. Czekster

    Nucleoside analogues have been extensively used to treat viral and bacterial infections and cancer for more than 60 years. However, their chemical synthesis is complex and often requires multiple steps and a dedicated synthetic route for every new nucleoside to be produced. Wild type nucleoside 2'-deoxyribosyltransferase enzymes are promising for biocatalysis. Guided by the structure of the enzyme from the thermophilic organism Chroococcidiopsis thermalis PCC 7203 (CtNDT) bound to the ribonucleoside analogue Immucillin-H, we designed mutants of CtNDT and the psychrotolerant Bacillus psychrosaccharolyticus (BpNDT) to improve catalytic efficiency with 3'-deoxynucleosides and ribonucleosides, while maintaining nucleobase promiscuity to generate over 100 distinct nucleoside products. Enhanced catalytic efficiency toward ribonucleosides and 3'-deoxyribonucleosides occurred via gains in turnover rate, rather than improved substrate binding. We determined the crystal structures of two engineered variants as well as kinetic parameters with different substrates, unveiling molecular details underlying their expanded substrate scope. Our rational approach generated robust enzymes and a roadmap for reaction conditions applicable to a wide variety of substrates.


  • Open Access

    Improved nucleoside (2’-deoxy)ribosyltransferases maximize enzyme promiscuity while maintaining catalytic efficiency

    by Peijun (Gary) Tang, Greice M. Zickuhr, Alison L. Dickson, Christopher J. Harding, Suneeta Devi, Tomas Lebl, David J. Harrison, Rafael G. da Silva, Clarissa M. Czekster

    Nucleoside analogues have been extensively used to treat viral and bacterial infections and cancer for the past 60 years. However, their chemical synthesis is complex and often requires multiple steps and a dedicated synthetic route for every new nucleoside to be produced. Wild type nucleoside 2′-deoxyribosyltransferase enzymes are promising for biocatalysis. Guided by the structure of the enzyme from the thermophilic organism Chroococcidiopsis thermalis PCC 7203 ( Ct NDT) bound to the ribonucleoside analogue Immucillin-H, we designed mutants of Ct NDT and the psychrotolerant Bacillus psychrosaccharolyticus ( Bp NDT) to improve catalytic efficiency with 3′-deoxynucleosides and ribonucleosides, while maintaining nucleobase promiscuity to generate over 100 distinct nucleoside products. Enhanced catalytic efficiency towards ribonucleosides and 3′-deoxyribonucleosides occurred via gains in turnover rate, rather than improved substrate binding. We determined crystal structures of two engineered variants as well as kinetic parameters with different substrates, unveiling molecular details underlying their expanded substrate scope. Our rational approach generated robust enzymes and a roadmap for reaction conditions applicable to a wide variety of substrates. Insert Table of Contents artwork here:

  • Open Access

    Broad substrate scope C-C oxidation in cyclodipeptides catalysed by a flavin-dependent filament

    by Emmajay Sutherland, Christopher J. Harding, Tancrède du Monceau de Bergendal, Gordon J. Florence, Katrin Ackermann, Bela E. Bode, Silvia Synowsky, Ramasubramanian Sundaramoorthy, Clarissa Melo Czekster

    Cyclic dipeptides are produced by organisms across all domains of life, with many exhibiting anticancer and antimicrobial properties. Oxidations are often key to their biological activities, particularly C-C bond oxidation catalysed by tailoring enzymes including cyclodipeptide oxidases. These flavin-dependent enzymes are underexplored due to their intricate three-dimensional arrangement involving multiple copies of two distinct small subunits, and mechanistic details underlying substrate selection and catalysis are lacking. Here, we determined the structure and mechanism of the cyclodipeptide oxidase from the halophile Nocardiopsis dassonvillei (NdasCDO), a component of the biosynthetic pathway for nocazine natural products. We demonstrated that NdasCDO forms filaments in solution, with a covalently bound flavin mononucleotide (FMN) cofactor at the interface between three distinct subunits. The enzyme exhibits promiscuity, processing various cyclic dipeptides as substrates in a distributive manner. The reaction is optimal at high pH and involves the formation of a radical intermediate. Pre-steady-state kinetics, a significant solvent kinetic isotope effect, and the absence of viscosity effects suggested that a step linked to FMN regeneration controlled the reaction rate. Our work elucidates the complex mechanistic and structural characteristics of this dehydrogenation reaction, positioning NdasCDO as a promising biocatalyst and expanding the FMN-dependent oxidase family to include enzyme filaments.


  • Open Access

    Immobilized Nucleoside 2′-Deoxyribosyltransferases from Extremophiles for Nucleoside Biocatalysis

    by Saúl Antonio Hernández Martínez, Peijun Tang, Roberto Parra-Saldívar, Elda M. Melchor-Martínez, Clarissa Melo Czekster

    The synthesis of nucleosides is crucial for pharmaceutical and biotechnological applications, acting as drugs and as essential building blocks for numerous therapeutic agents. However, most enzymes employed in nucleoside biocatalysis are not recycled, possess limited stability, and have strict substrate selection for ribonucleosides or 2'deoxyribonucleosides. We employed 2'-deoxyribonucleoside transferase (NDT) enzymes from thermophilic and psychrophilic bacteria to demonstrate they can be immobilized to enhance specific activity, stability, and recyclability. NDT enzymes from Chroococcidiopsis thermalis (CtNDT), and Bacillus psychrosaccharolyticus (BpNDT) were immobilized by covalent attachment to chitosan beads. A double mutant of CtNDT, capable of generating 3'deoxyribonucleosides, showed remarkable and increased stability after immobilization compared to the same enzyme in the solution. Furthermore, we demonstrated the recyclability of immobilized biocatalysts, with a 10-fold improvement in reaction yield over 20 consecutive cycles, highlighting the practicality and sustainability of the developed immobilization method. We used our strategy to produce a pharmaceutically relevant 3'deoxyribonucleoside (2-fluoro-3'-deoxyadenosine). This highlights the importance of efficient immobilization techniques to enhance the catalytic properties of NDT enzymes, expanding their utility in biocatalysis.


  • Open Access

    Immobilized Nucleoside 2′-Deoxyribosyltransferases from Extremophiles for Nucleoside Biocatalysis

    by Saúl Antonio Hernández Martínez, Peijun Tang, Roberto Parra-Saldívar, Elda M. Melchor-Martínez, Clarissa Melo Czekster

    The synthesis of nucleosides is crucial for pharmaceutical and biotechnological applications, acting as drugs and as essential building blocks for numerous therapeutic agents. However, most enzymes employed in nucleoside biocatalysis are not recycled, possess limit stability and strict substrate selection for ribonucleosides or 2′deoxyribonucleosides. We employed 2′deoxyribonucleoside transferase (NDT) enzymes from thermophilic and psychrophilic bacteria to demonstrate they can be immobilized to en-hance specific activity, stability, and recyclability. NDT enzymes from Chroococcidiopsis thermalis (CtNDT), and Bacillus psychrosaccharolyticus (BpNDT) were immobilized by covalent attachment to chitosan beads. A double mutant of CtNDT, capable of generating 3′deoxyribonucleosides, showed remarkable and increased stability after immobilization when compared to the same enzyme in solution. Furthermore, we demonstrated the recyclability of immobilized biocatalysts, with a tenfold improvement in reaction yield over 20 consecutive cycles, highlighting the practicality and sustainability of the developed immobilization method. We used our strategy to produce a pharmaceutically relevant 3′deoxyribonucleoside (2-fluoro-3′-deoxyadenosine). This highlights the importance of efficient immobilization techniques to enhance catalytic properties of NDT enzymes, expanding their utility in biocatalysis.

  • Open Access

    The Immobilization of a Cyclodipeptide Synthase Enables Biocatalysis for Cyclodipeptide Production

    by Lynette Alvarado-Ramírez, Emmajay Sutherland, Elda M. Melchor-Martínez, Roberto Parra-Saldívar, Alfredo D. Bonaccorso, Clarissa Melo Czekster

    Cyclodipeptide synthases (CDPSs) are enzymes that use aminoacylated tRNAs as substrates to produce cyclic dipeptide natural products acting as anticancer and neuroprotective compounds. Many CDPSs, however, suffer from instability and poor recyclability, while enzyme immobilization can enhance catalyst efficiency and reuse. Here, the CDPS enzyme from Parcubacteria bacteriumRAAC4_OD1_1 was immobilized using three different supports: biochar from waste materials, calcium-alginate beads, and chitosan beads. Immobilization of active PbCDPS was successful, and production of the cyclodipeptide cyclo (His-Glu) (cHE) was confirmed by HPLC-MS. Biochar from spent coffee activated with glutaraldehyde, alginate beads, and chitosan beads activated with glutaraldehyde led to a 5-fold improvement in cHE production, with the immobilized enzyme remaining active for seven consecutive cycles. Furthermore, we co-immobilized three enzymes participating in the cascade reaction yielding cHE (PbCDPS, histidyl-tRNA synthetase, and glutamyl-tRNA synthetase). The enzymatic cascade successfully produced the cyclic dipeptide, underscoring the potential of immobilizing various enzymes within a single support. Importantly, we demonstrated that tRNAs remained free in solution and were not adsorbed by the beads. We paved the way for the immobilization of enzymes that utilize tRNAs and other complex substrates, thereby expanding the range of reactions that can be exploited by using this technology.